Browse Infectious Disease General

Intradermal JYNNEOS may safely provide populations that have been disproportionately affected by monkeypox with rapid access to a limited resource without sacrificing the level of immune response achieved.

In this issue of the Journal, Thornhill et al. report on 528 persons with monkeypox in a cohort spanning 16 countries on five continents.¹ The authors provide important demographic, epidemiologic, and clinical details on the largest reported cohort of patients in the latest emerging infectious disease...

In this report, 528 cases of monkeypox across 16 countries are described. Rash, mucosal lesions, fever, lethargy, and lymphadenopathy were common clinical findings. Few patients were hospitalized.

A patient in whom Japanese encephalitis was diagnosed in February 2021 has been identified as a likely sentinel human case of the 2022 outbreak of the disease in Australia.

Tecovirimat might speed resolution of monkeypox illness and improve outcomes, but how can we manage compassionate access to a drug whose safety and efficacy in humans have not been established?

In this trial involving overweight or obese outpatients with Covid-19, investigators found that none of three repurposed drugs (metformin, ivermectin, and fluvoxamine) reduced the risk of serious disease.

In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the Covid-19 pandemic, some of the early treatment trials were rushed, leading to studies that were badly conducted¹ or had too few patients.

In this ongoing household cohort study in Nicaragua, previous SARS-CoV-2 infection during a second Covid-19 wave provided some protection against symptomatic Covid-19, with greater protection against severe illness.

A 31-year-old man was admitted with perianal and penile ulcers, rectal pain, and vesiculopustular rash. He had first noticed itchy white “bumps” around the anus 9 days earlier. A diagnostic test was performed.

This phase 1 trial examined an engineered monoclonal antibody, L9LS, targeting the sporozoite. L9LS protected against malaria infection in a human challenge model.

Monoclonal antibodies are commonly used in the treatment of diseases, including cancer. A next-generation antibody for the prevention of malaria exploits different vulnerabilities of Plasmodium falciparum, the major cause of malaria.